Daniel C Chan
Overview
Explore the profile of Daniel C Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1004
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pozhitkov A, Lindahl E, Chan D
Cureus
. 2024 Jan;
15(12):e49907.
PMID: 38174166
Background Titanium dental implants (e.g., Nobel Biocare, Switzerland) are routinely used as support for dental restoration. Titanium has been the material of choice due to its corrosion resistance and ability...
2.
Ghosh R, Ganapathy M, Alworth W, Chan D, Kumar A
J Steroid Biochem Mol Biol
. 2021 Aug;
213:105962.
PMID: 34411848
No abstract available.
3.
Van Duker M, Hayashi J, Chan D, Tagami J, Sadr A
Am J Dent
. 2019 Jul;
32(3):143-146.
PMID: 31295396
Purpose: To evaluate the microtensile bond strength (MTBS) of resin composite to demineralized dentin treated with SDF or SDF-KI. Methods: Occlusal enamel of 30 caries-free extracted human molars was removed...
4.
Leonard S, Lee H, Gaddy D, Klinz S, Paz N, Kalra A, et al.
Anticancer Drugs
. 2017 Sep;
28(10):1086-1096.
PMID: 28857767
Liposomal irinotecan (irinotecan liposome injection, nal-IRI), a liposomal formulation of irinotecan, is designed for extended circulation relative to irinotecan and for exploiting discontinuous tumor vasculature for enhanced drug delivery to...
5.
Scarborough H, Helfrich B, Casas-Selves M, Schuller A, Grosskurth S, Kim J, et al.
Clin Cancer Res
. 2016 Sep;
23(6):1531-1541.
PMID: 27663586
The emergence of EGFR inhibitors such as gefitinib, erlotinib, and osimertinib has provided novel treatment opportunities in EGFR-driven non-small cell lung cancer (NSCLC). However, most patients with EGFR-driven cancers treated...
6.
Yu H, Batenchuk C, Badzio A, Boyle T, Czapiewski P, Chan D, et al.
J Thorac Oncol
. 2016 Sep;
12(1):110-120.
PMID: 27639678
Introduction: Therapeutic antibodies to immune checkpoints show promising results. Programmed death-ligand 1 (PD-L1), an immune checkpoint ligand, blocks the cancer immunity cycle by binding the PD-L1 receptor (programmed death 1)....
7.
Helfrich B, Kim J, Gao D, Chan D, Zhang Z, Tan A, et al.
Mol Cancer Ther
. 2016 Aug;
15(10):2314-2322.
PMID: 27496133
Small-cell lung cancer (SCLC) cells have rapid proliferation, universal Rb inactivation, and high rates of MYC family amplification, making aurora kinase inhibition a natural target. Preclinical studies have demonstrated activity...
8.
Moody T, Chan D, Mantey S, Moreno P, Jensen R
Life Sci
. 2014 Feb;
100(1):25-34.
PMID: 24496038
Aims: The mechanism by which SR48692 inhibits non-small cell lung cancer (NSCLC) proliferation was investigated. Main Methods: The ability of SR48692 to inhibit the proliferation of NSCLC cell lines NCI-H1299...
9.
Casas-Selves M, Kim J, Zhang Z, Helfrich B, Gao D, Porter C, et al.
Cancer Res
. 2012 Jun;
72(16):4154-64.
PMID: 22738915
Lung cancer is the leading cause of death worldwide. Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal...
10.
Gladstone M, Frederick B, Zheng D, Edwards A, Yoon P, Stickel S, et al.
Dis Model Mech
. 2012 Feb;
5(3):342-50.
PMID: 22344740
We described previously a screening protocol in Drosophila melanogaster that allows us to identify small molecules that increase the killing effect of ionizing radiation in vivo in a multicellular context....